The development and application of pyrosequencing assays to determine antiviral susceptibility of Influenza A to neuraminidase inhibitors.

0044 English OPEN
Gatica-Wilcox, Bree;
  • Subject: QR180 | R1
    mesheuropmc: viruses | respiratory tract diseases | virus diseases

Influenza A can result in complicated disease and death in high risk individuals, and can be treated with the neuraminidase inhibitors oseltamivir and zanamivir. During the 2007-2008 season a rise in oseltamivir resistance in H1N1 viruses was observed worldwide. This re... View more
  • References (26)
    26 references, page 1 of 3

    Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Maramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Susuki Y & Kawaoka Y. 2005. Isolation of Drug-Resistant H5N1 Virus. Nature, Vol 437, 1108.

    Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS & Mendel DB. 1998. Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071. Antimicrobial Agents and Chemotherapy, Vol 42, No 3, 647-653.

    Lindstrom S, Garten R, Balish A, Shu B, Emery S, Berman L, Barnes N, Sleeman K, Gubareva L, Villanueva J & Klimov A. 2012. Human Infections with Novel Reassortant Influenza A(H3N2)v Viruses, United States, 2011. Emerging Infectious Diseases, Vol 18, No 5, 834-7.

    Liu CM, Driebe EM, Schupp J, Kelley E, Nguyen JT, McSharry JJ, Weng Q, Engelthaler DM & Keim PS. 2010. Rapid Quantification of SingleNucleotide Mutations in Mixed Influenza A Viral Populations Using Allele-Specific Mixture Analysis. Journal of Virological Methods, Vol 163. 109-115.

    Mahony JB, Petrich A & Smieja M. 2011. Molecular Diagnosis of Respiratory Virus Infections. Critical Reviews in Clinical laboratory Sciences, Vol 48, No 5-6, 217-249.

    Malakov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, Mishin VP, Hayden FG, Kim DH, Ing A, Campbell ER, Yu M & Fang F. 2006. Sialidase Fusion Protein as a Novel BroadSpectrum Inhibitor of Influenza Virus Infection. Antimicrobial Agents and Chemotherapy, Vol 50, No 4, 1470-79.

    Matthews JT. 2006. Egg-based Production of Influenza Vaccine: 30 Years of Commercial Experience. The Bridge, 17-30.

    McKimm-Breschkin J, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ, Bethell RC & Varghese JN. 1998. Mutations in a Conserved Residue in the Influenza Virus Neuraminidase Active Site Decreases Sensitivity to Neu5Ac2en-Derived Inhibitors. Journal of Virology, Vol 72, No 3, 2456-62.

    McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, Hayden F & Zambon M. 2003. Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir. Antimicrobial Agents and Chemotherapy, Vol 47, No 7, 2264-2272.

    McSharry JJ, McDonough AC, Olson BA & Drusano GL. 2004. Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors. Clinical and Diagnostic Laboratory Immunology, Vol 11, No 1, 21-28.

  • Similar Research Results (3)
  • Metrics
Share - Bookmark